MedStar Authors catalog › Details for: Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial.
Normal view MARC view ISBD view

Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial.

by Zorowitz, Richard D.
Citation: Pm & R. 2018 Jun 30.Journal: PM & R : the journal of injury, function, and rehabilitation.Published: 2018ISSN: 1934-1482.Full author list: Zorowitz RD; Alexander DN; Formella AE; Ledon F; Davis C; Siffert J.UI/PMID: 29964212.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar National Rehabilitation NetworkActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.pmrj.2018.06.003 (Click here) Abbreviated citation: PM R. 2018 Jun 30.Abstract: BACKGROUND: Dextromethorphan (DM) / quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based on efficacy and safety trials in patients with PBA caused by amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia, or traumatic brain injury.Abstract: OBJECTIVE: To report results from the stroke cohort of PRISM II, including the Stroke Impact Scale (SIS).Abstract: DESIGN: Open-label trial evaluating twice-daily DM/Q over 90 days.Abstract: STUDY PARTICIPANTS: Adults (n = 113) with a clinical diagnosis of PBA secondary to stroke; stable psychiatric medications were allowed.Abstract: METHODS: PRISM II was an open-label, 12-week trial enrolling adults with PBA caused by dementia, stroke (reported here), or TBI. All study participants received DM/Q 20/10 mg twice daily. Study visits occurred at baseline and at days 30 and 90.Abstract: SETTING: 150 U.S. centers.Abstract: MAIN OUTCOME MEASUREMENTS: Primary efficacy measure was changed from baseline to day 90 in Center for Neurologic Study-Lability Scale (CNS-LS) scores. Secondary outcomes included PBA episodes (estimated over 7 days), Clinical and Patient/Caregiver Global Impression of Change (CGI-C and PGI-C), Quality of Life-Visual Analog Scale (QOL-VAS), SIS, Patient Health Questionnaire (PHQ-9), and Mini-Mental State Examination (MMSE).Abstract: RESULTS: Compared with baseline, CNS-LS scores (SD) improved by -6.2 (6.1, P<.001) at day 30 and -7.6 (6.7, P<.001) at day 90. PBA episodes were reduced by 65% and 75% at day 30 and 90, respectively. Seventy-five percent of clinicians and 67% of patients/caregivers rated PBA as much or very much improved. All SIS items significantly improved from baseline (P<.05, all). Adverse events included diarrhea (4.4%), headache (3.5%), constipation (2.7%), and dizziness (2.7%); 5.3% had adverse events leading to study discontinuation.Abstract: CONCLUSIONS: DM/Q effectively treated PBA and was associated with global and functional improvement; adverse events were consistent with the known safety profile of DM/Q.Abstract: Copyright (c) 2018 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.

Powered by Koha